We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Invitrogen Launches 60 Division Arrested Cell Lines

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Invitrogen Corporation launches the first suite of 60 division arrested cell lines for screening a broad range of therapeutic targets.

Generated through a proprietary treatment of dividing cells, division arrested cells do not require lengthy and laborious cell culture procedures to prepare live cells for screening assays. Division arrested cells may be plated and assayed within 24 hours of thawing, and cell numbers increase only marginally after plating, thereby removing the variability caused by cell division during the course of an assay and providing more consistent results.

Division arrested cells show agonist-induced responses virtually indistinguishable from that of dividing cells, and exhibit no toxicity or apparent changes in signal transduction, ensuring researchers obtain the correct pharmacological profile.

The collection includes a broad range of cell lines developed for functional cell-based assays of G-protein coupled receptors, nuclear hormone receptors and hERG. The cell lines are available in two configurations: 1 x 384-well plate assay kits (including detection reagents) for small scale screening or evaluation purposes, and 10 x 384-well-plate kits for small to large scale screening.

Invitrogen acquired division arrest technology last year through the acquisition of Sentigen Corporation. As part of the Sentigen transaction, Invitrogen owns the patent family which includes U.S. Patent No. 7,045,281 and Australian Patent No. 2003270073.